Tuesday, June 11, 2019 Daily Archives

Servier selects Yposkesi for viral vector supply

by

The deal brings Servier access to CDMO Yposkesi’ lentiviral vector production for its Phase I allogeneic CAR-T candidate UCART19. Servier has chosen contract development manufacturing and organization (CDMO) Yposkesi to provide the lentiviral vectors for its candidate UCART19, an off-the-shelf chimeric antigen receptor (CAR) T-cell in trials for haematological malignancies. According to the firm, its selection of fellow French CDMO came “after testing lentiviral vectors from several competitors and comparing the costs,†though financial and timelines details have not been…

June 11, 2019

Merck in $773m deal to add preclinical MAb firm Tilos

by

Merck & Co. has reached an agreement to acquire Tilos Therapeutics, a developer of monoclonal antibodies targeting the latent TGFβ complex. The deal will see biopharma firm Merck acquire private Massachusetts-based biotech Tilos Therapeutics for up to $773 million (€683 million), including an undisclosed upfront payment and milestones. Dean Li, senior vice president, discovery and translational medicine, Merck Research Laboratories, said in a statement the deal is evidence of the firm’s continued efforts to enhance its pipeline. “Tilos has developed…

June 11, 2019